19 DCVMN members involved in R&D for 22 potential vaccines. Out of these, 4 members’ are executing Phase 1 or ½ of clinical trials, and the remaining vaccines were in the preclinical phase in May 2020.

DCVMN Research, Development, and Technology

- DCVMN past supply history
- projected cost 

Factors for Scaling

Filling and finishing is the final stage in the process of vaccine manufacturing and also the most vulnerable to experiencing congestion in production. There are a number of possible solutions for this issue:
-Facilities producing influenza vaccine are likely to have excess capacity for manufacturing
-Adding shifts 
-Companies with a lot of staff and resources are leading the way in building the filling capacity for COVID vaccines
-14 DCVMN members with excess capacity and resources have expressed their capabilities and willingness to tackle surge manufacturing or filling. - --Many members have available resources for formulation and fill-finish.
-Fixing holes in the supply chain



Fill-finish and distribution

About 50 different vaccines for conditions other than COVID-19 are produced or distributed by members of the DCVMN.

Supply of Other Vaccines

Compilation of 2019 data, online research about COVID-19 vaccine activity by DCVMN organizations, and supply capacity surveys were used to analyze the potential of DCVMN member organizations in the following areas:
- Research, Development, and Technology
- Scaling
- Fill-finish and distribution
- Supply of other vaccines

Stanford University

DCVMN, or the Developing Countries Vaccine Manufacturers Network, is a cohort of 41 multinational vaccine manufacturers in Africa, the Middle East, Latin America, and Asia involved in vaccine development from the research to supply stages. The manufacturers work to benefit both local communities as well as international consumers, and they have contributed to the efforts against coronavirus. 13 of the DCVMN organizations have an understanding of international regulations for supply, as well as vaccines with WHO-prequalified vaccine status. 

DCVMN Involvement

Pagliusi, S., Jarrett, S., Hayman, B., Kreysa, U., Prasad, S. D., Reers, M., Hong Thai, P., Wu, K., Zhang, Y. T., Baek, Y. O., Kumar, A., Evtushenko, A., Jadhav, S., Meng, W., Dat, D. T., Huang, W., & Desai, S. (2020). Emerging manufacturers engagements in the COVID -19 vaccine research, development and supply. Vaccine, 38(34), 5418–5423. https://doi.org/10.1016/j.vaccine.2020.06.022

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287474/

Learn Before

Related

Learn After